Cures Act Passes Overwhelmingly in the House

The Cures Act passed in the House yesterday. Its 392 to 26 vote suggests that your congressional delegation voted for the Act’s investment in NIH’s management of new and important basic life science research by national labs and research universities. Now (as explained yesterday) you can thank them and while doing so, explain how Bayh-Dole’s commercialization of their investment can attract private sector financial support for patented promising results, leveraging Cures Act congressional appropriations up to ten times by through research university and private sector partnership development initiatives at private sector cost and risk. Such Bayh-Dole investments are absolutely dependent on strong reliable patents obtained by research universities. Continue reading Cures Act Passes Overwhelmingly in the House

Bayh-Dole Explained on Capital Hill

Earlier this week those able to attend were treated to an excellent and important presentation on Capitol Hill discussing the Bayh-Dole Act. It was sponsored by Eagle Forum, whose recently deceased founder Phyllis Schlafly, was a tireless conservative defender of intellectual property. Eagle Forum’s Jim Edwards acted as Moderator. The panelist experts were; erstwhile B-D defender Joe Allen, AUTM’s Stephen Susalka and LES’ Brian O’Shaughnessy. The presentation was illuminating and informative. It definitely is worthy of broader circulation, especially to our congressional delegations. Continue reading Bayh-Dole Explained on Capital Hill

President Elect Trump and Tech Meet This Coming Weekend

Sometimes pictures say a thousand words. This iconic photo from 2011 marked  the marriage of President Obama and Silicon Valley IT tech.

Obama dinner with tech titans
President Obama’s Silicon Valley Tech Titans Dinner, 2/18/2011

No doubt its agenda included the Obama Administration Patent Reform Initiative and its HR 9 and S.1137 measures the President said he was eager to sign.  Continue reading President Elect Trump and Tech Meet This Coming Weekend

Yes, But Then There’s Peter Thiel

Peter Thiel, the Silicon Valley superstar who co-founded PayPal, Palantir, and sits on Facebook’s board has joined President Elect Trump’s transition team. His brilliance and unique tech background in a group of NY business folks will be uniquely influential, which calls into agonizing question the glass-half-full optimism explained so well this week in IPWatchdog posts co-authored by Peter Harter and Gene Quinn.  Continue reading Yes, But Then There’s Peter Thiel

China and US Head in Opposite IP Directions

China increasingly a preferred venue for patent litigation, even for US patent owners

Quoted below are the closing paragraphs of IPWatchdog’s post today co-authored by Steve Brachmann and Gene Quinn.

The entire piece is well worth reading. The warning in its closing sentence (below) is must reading. China is strengthening its patent system while we are weakening ours. Continue reading China and US Head in Opposite IP Directions

Replace and Thus Repeal Bayh-Dole Commercialization

Whatever its outcome, this election marks the start of political turmoil for months to come. In the coming “fog of war”, anti-patent activists will seek fresh support for stale schemes to crush Bayh-Dole’ (B-D’s) commercialization cornerstone. Mega-tech muscle will push new versions of HR 9 litigation on Capitol Hill. Continue reading Replace and Thus Repeal Bayh-Dole Commercialization

State Level Anti-commercialization Bill Aimed at Universities

The Electronic Frontier Foundation (EFF) is a powerful DC trade association home page dedicated to eliminating software patents.  But its legislative proposals often sabotage investment in all patents, undermining technology’s development at every level, especially at commercialization’s TTO beginnings. EFF’s Capitol Hill objectives still include passing HR 9 and S 1137 by fanning the phony flames of a the extinguished patent troll litigation crisis (here), signaling continued strong support for HR 9 and S. 1137 and their follow-on counterparts in coming sessions. Continue reading State Level Anti-commercialization Bill Aimed at Universities

The Patent War Will Soon Resume, But Our Voices Are Also Being Heard

Below are excerpts from a letter we received from renowned DC patent attorney Rob Sterne, who with other IP experts attended a meeting with senior Clinton policy-makers to discuss IP issues. Excerpts from his letter indicate that if elected, Clinton IP policy advisors’ folks have been made aware of the controversy surrounding perennial anti-patent efforts to further shield efficient infringement from the congressional and judicial fates it deserves. This time our side of the argument is being heard before being preempted by the IT mega-techs. In the closing paragraph below, Rob astutely warns that after the election, anti-patent rhetoric will escalate, why political pressure is inevitable and why we must continue weighing-in directly. Continue reading The Patent War Will Soon Resume, But Our Voices Are Also Being Heard

Urge 21st Century Cures Act Passage This Year

Having accomplished little leading to November’s election it seems something good actually may clear Congress during the coming lame duck session. A research boosting bill with leadership approval, bi-partisan, bi-cameral floor support, and backed by research universities is gaining pre-election traction for passage in the post-election lame duck session. Described (below) in a Morning Consult piece containing informative links to life science community letters urging lame duck passage, the 21st Century Cures Act bolsters life science with sequestration-starved FDA and NIH funding. Continue reading Urge 21st Century Cures Act Passage This Year